Opinion|Videos|November 21, 2025
Unintended Consequences of Metric Changes
Panelists discuss how substituting LDL outcomes with statin-use metrics weakened cholesterol management quality.
Advertisement
Episodes in this series
Panelists discuss how replacing outcome-driven low-density lipoprotein (LDL) targets with process-based statin-use measures led to unintended negative consequences. Clinicians began meeting performance goals without necessarily improving patient outcomes.
They note that the lack of specific targets fostered complacency and variability in practice standards. Health systems measured success by statin prescription rates rather than LDL reduction or cardiovascular prevention.
Panelists conclude that quality measures must prioritize outcomes over process metrics to restore the focus on meaningful patient improvements.
Advertisement
Related to this article
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
3
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5